2’-氯联苯-4-甲醛 | 39802-78-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2’-氯联苯-4-甲醛
• 中文别名: 2'-氯联苯-4-甲醛；4-(2-氯苯基)苯甲醛
• 英文名称: 4-(2-chloro-phenyl)-benzaldehyde
• 英文别名: 2'-chloro-[1,1'-biphenyl]-4-carbaldehyde；2'-chlorobiphenyl-4-carbaldehyde；4-(chlorophenyl)benzaldehyde；2'-chloro-4-biphenyl-carboxaldehyde；4-(2'-chlorophenyl)benzaldehyde；4-(2-Chlorophenyl)benzaldehyde
• CAS: 39802-78-3
• 化学式: C₁₃H₉ClO
• 分子量: 216.667
• InChiKey: PGMYZSDMJRFWKS-UHFFFAOYSA-N

物化性质

• 沸点：
  338.9±25.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(2-Chlorophenyl)benzaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(2-Chlorophenyl)benzaldehyde
CAS number: 39802-78-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H9ClO
Molecular weight: 216.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2’-氯联苯-4-甲醛 生成 2-[4-(2-Chloro-phenyl)-phenyl]-1H-benzoimidazole-5-carboxylic Acid Amide
  参考文献：
  名称：

  Substituted benzimidazoles and imidazo-[4,5]-pyridines

  摘要：

  2-芳基取代苯并咪唑和咪唑[4,5]吡啶被披露为Cds1的抑制剂，并在癌症治疗中作为化疗或放疗的辅助剂。

  公开号：

  US20030176438A1
• 作为产物：
  描述：

  4-联苯-2-氯羧酸 在 lithium aluminium tetrahydride 、 boron trifluoride methanol complex 、 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 生成 2’-氯联苯-4-甲醛
  参考文献：
  名称：

  Brown, John W.; Butcher, Jane L.; Byron, David J., Molecular Crystals and Liquid Crystals (1969-1991), 1988, vol. 159, p. 255 - 266

  摘要：

  DOI：

文献信息

• Gold Catalysts Can Generate Nitrone Intermediates from a Nitrosoarene/Alkene Mixture, Enabling Two Distinct Catalytic Reactions: A Nitroso-Activated Cycloheptatriene/Benzylidene Rearrangement
  作者：Sayaji Arjun More、Rahul Dadabhau Kardile、Tung-Chun Kuo、Mu-Jeng Cheng、Rai-Shung Liu

  DOI：10.1021/acs.orglett.1c01857

  日期：2021.7.16

  Gold-catalyzed reactions of cycloheptatrienes with nitrosoarenes yield nitrone derivatives efficiently. This reaction sequence enables us to develop gold-catalyzed aerobic oxidations of cycloheptatrienes to afford benzaldehyde derivatives using CuCl and nitrosoarenes as co-catalysts (10–30 mol %). Our density functional theory calculations support a novel nitroso-activated rearrangement, tropylium

  环庚三烯与亚硝基芳烃的金催化反应可有效地产生硝酮衍生物。该反应序列使我们能够开发金催化的环庚三烯有氧氧化，以使用 CuCl 和亚硝基芳烃作为助催化剂（10-30 mol%）提供苯甲醛衍生物。我们的密度泛函理论计算支持一种新的亚硝基活化重排，tropylium → 亚苄基。使用相同的亚硝基芳烃，我们在亚硝基苯和两个烯醇醚之间开发了金催化的 [2 + 2 + 1]-环化，以使用 1,4-环己二烯作为氢供体产生 5-烷氧基异恶唑烷。
• [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] AGENTS RECEPTEURS DE L'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005097740A1

  公开（公告）日：2005-10-20

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了具有组合物(I)或其药学上可接受的盐的新颖化合物，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含组合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  申请人：Beavers Lisa Selsam

  公开号：US20100048580A1

  公开（公告）日：2010-02-25

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了化合物(I)的新颖化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施方案中，本发明公开了包含化合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• [EN] SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] 3- ET 4- AMINOMETHYLPIPERIDINES SUBSTITUEES UTILISEES COMME BETA-SECRETASE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004002483A1

  公开（公告）日：2004-01-08

  The invention relates to novel compounds, which are substituted chiral or achiral derivatives of 3- or 4- aminomethylpiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula (I) and especially their use as inhibitors of beta-secretases for the treatment of Alzheimer’s disease.

  本发明涉及新型化合物，其为通式（I）的3-或4-氨基甲基哌啶的取代手性或非手性衍生物。本发明还涉及包括制备这些化合物的工艺、含有一种或多种通式（I）化合物的药物组合物以及特别是它们作为β-分泌酶抑制剂用于治疗阿尔茨海默病的相关方面。
• Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase
  作者：Katherine A. Hurley、Thiago M. A. Santos、Molly R. Fensterwald、Madhusudan Rajendran、Jared T. Moore、Edward I. Balmond、Brice J. Blahnik、Katherine C. Faulkner、Marie H. Foss、Victoria A. Heinrich、Matthew G. Lammers、Lucas C. Moore、Gregory D. Reynolds、Galen P. Shearn-Nance、Brian A. Stearns、Zi W. Yao、Jared T. Shaw、Douglas B. Weibel

  DOI：10.1039/c7md00012j

  日期：——

  potent inhibitors of DNA gyrase and are active against clinical strains of Gram-negative bacteria (Escherichia coli, Shigella flexneri, and Salmonella enterica; 3 of 10 wild-type strains tested) and Gram-positive bacteria (Bacillus spp., Enterococcus spp., Staphylococcus spp., and Streptococcus spp.; all 9 of the wild-type strains tested). E. coli strains resistant to the DNA gyrase inhibitors ciprofloxacin

  细菌DNA促旋酶是一种必不可少的II型拓扑异构酶，可使细胞克服复制，转录，重组和修复过程中遇到的拓扑障碍。该酶在细菌中无处不在，代表了抗菌治疗的重要临床目标。在本文中，我们从183个衍生物库中报告了三种激动人心的新型回旋酰胺类似物的表征，它们是DNA回旋酶的有效抑制剂，对革兰氏阴性菌（大肠杆菌，志贺氏志贺氏菌和肠炎沙门氏菌；测试的10种野生型菌株中有3种）和革兰氏阳性菌（芽孢杆菌，肠球菌，葡萄球菌spp。，and Streptococcus spp .; 所有9种野生型菌株都进行了测试）。对DNA促旋酶抑制剂环丙沙星和新霉素具有抗性的大肠杆菌菌株对这些新的乙二酰胺具有极小的交叉抗性。体外研究表明，新的类似物可有效抑制DNA促旋酶的DNA超螺旋活性（IC 50值为47–170 nM），但不会改变酶的ATPase活性。尽管赋予细菌细胞对这些新的回旋酰胺抗性的突变会映射到编码DNA回旋酶亚基的基